Idoxifene: A novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats

Endocrinology

Volumn 139, Issue 12, 1998, Pages 5224-5234

  Nuttall, Mark E ^a   Bradbeer, Jeremy N ^a   Stroup, George B ^a   Nadeau, Daniel P ^a   Hoffman, Sandra J ^a   Zhao, Hugh ^a   Rehm, Sabine ^a   Gowen, Maxine ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR MODULATOR; IDOXIFENE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HORMONE RECEPTOR INTERACTION; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; UTERUS WEIGHT;

EID: 0031725563     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.139.12.6343     Document Type: Article

References (46)

1. Lindsay R 1988 Sex steroids in the pathogenesis and prevention of osteoporosis. In: Riggs BL (ed) Osteoporosis: Etiology, Diagnosis and Management. Raven Press, New York, pp 333-358
2. Barzel US 1988 Estrogens in the prevention and treatment of postmenopausal osteoporosis: a review. Am J Med 85:847-850
3. Grodstein F, Stampfer MJ 1995 The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 38:199-210
4. Daley E, Roche M, Barlow D 1992 HRT: an analysis of benefits, risks and costs. Br Med Bull 42:368-400
5. Hosking DJ 1990 Osteoporosis: problems for the future. In: Smith R (ed) Osteoporosis, Royal College of Physicians, London, pp 199-208
6. Barrett-Connor E 1992 Hormone replacement and cancer. Br Med Bull 48:345-355
7. Grainger DJ, Metcalfe JC 1996 Tamoxifen: teaching an old drug new tricks?. Nat Med 2:381-385
8. Yang NN, Venugopalan M, Hardikar S, Glasebrook A 1996 Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273:1222-1225
9. Ke HZ, Simmons HA, Piries CM, Crawford DT, Thompson DD 1995 Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136:2435-2441
10. Willson TM, Norris JD, Wagner BL, Asplin PB, Brown HR, Jones SS, Henke B, Sauls H, Wolfe S, Morris DC, McDonnell DP 1997 Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138:3901-3911
11. Bjarnason K, Skrumsager BK, Kiehr B 1997 Levormeloxifene, a new partial estrogen receptor agonist demonstrates antiresorptive and antiatherogenic properties in postmenopausal women. J Bone Miner Res [Suppl] 12:S346
12. Kauffman RF, Bryant HU 1995 Selective estrogen receptor modulators. DN& P 8:531-538
13. Yamashita S, Takayanagi A, Shimizu N 1996 Temporal and cell-type specific expression of c-fos and c-jun protooncogenes in the mouse uterus after estrogen stimulation. Endocrinology 137:5468-5475
14. Love RR, Cameron L, Connell BL, Leventhal H 1991 Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Int Med 151:1842-1847
15. McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M, Foster AB 1989 Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. J Med Chem 32:2527-2533
16. Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC 1991 Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res 51:5851-5858
17. Majeska RJ, Rodan SB, Rodan GA 1980 Parathyroid hormone-responsive clonal cell lines from rat osteosarcoma. Endocrinology 107:1494-1503
18. Migliaccio S, Davis VL, Gibson MK, Gray TK, Korach KS 1992 Estrogens modulate the responsiveness of osteoblast-like cells (Ros 17/2.8) stably transfected with estrogen receptor. Endocrinology 130:2617-2624
19. Clover J, Gowen M 1994 Are MG-63 and Hos TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype? Bone 15:585-591
20. Holinka CG, Hata H, Kuramoto H, Gurpide E 1986 Effects of steroid hormones and antisteroids on alkaline phosphatase activity in human endometrial cancer cells (Ishakawa line). Cancer Res 46:2771-2774
21. James IE, Dodds RA, Lee-Rykaczewski E, Eichman CF, Connor JR, Hart KA, Maleef BE, Lackman, RD, Gowen M 1996 Purification and characterization of fully functional human osteoclast precursors. J Bone Miner Res 11:1608-1618
22. Wen DX, Xu Y-F, Goldman MK, McDonnell P 1994 The A and B isoforms of the human progesterone receptor operate through distinct signalling pa thways within target cells. Mol Cell Biol 14:8356-8364
23. 22a.Beresford JN, Gallagher JA, Russell RGG 1986 1,25-dihydroxyvitamin D3 and human bone-derived cells in vitro: effects on alkaline phosphatase, type I collagen and proliferation. Endocrinology 119:1776-1785
24. Norris JD, Fan D, Wagner BL, McDonnell DP 1996 Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifene mixed agonist activity. Mol Endocrinol 10:1605-1616
25. Frenkel B, Mijnes J, Aronow MA, Zambetti G, Banerjee C, Stein JL, Lian JB, Stein GS 1993 Position and orientation-selective silencer in protein-coding sequences of the rat osteocalcin gene. Biochemistry 32:13636-13643
26. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen S 1996 Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 10:119-131
27. Nuttall ME, Nadeau D, Prichett WP, Gowen M 1997 Idoxifene, a tissue selective estrogen agonist/antagonist, has a mechanism of action in bone similar to estrogen and distinct from raloxifene. J Bone Miner Res [Suppl] 12:S170
28. Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, Manolagos SC 1992 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 89:883-891
29. Littlewood AJ, Russell J, Harvey G, Hughes DE, Russell RGG, Aarden L, Gowen M 1991 The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro. Endocrinology 129:1513-1520
30. Weinreb M, Shinar D, Rodan GA 1990 Different patterns of alkaline phosphatase, osteopontin and osteocalcin expression in developing rat bone by in situ hybridization. J Bone Min Res 5:831-842
31. Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC 1991 Avian osteoclasts as estrogen target cells. Pro Natl Acad Sci 88:6613-6617
32. Oursler MJ, Pederson L, Fitzpatrick L, Riggs BL, Spelsberg TC 1994 Human giant cell rumors of bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci 91:5227-5231
33. Hoyland JA, Mee AP, Brown J, Braidman IP, Mawer EB, Freemont AJ 1996 Use of in situ-reverse transcriptase-polymerase chain reaction to localise oestrogen receptor mRNA in bone. J Bone Miner Res 11:S221
34. Hughes DE, Dai A, Tifee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat Med 2:1132-1136
35. Jensen EV, DeSombre ER 1972 Mechanism of action of the female sex hormones. Annu Rev Biochem 41:203-230
36. Cauley JA, Lucas FL, Kuller FH, Vogt MT, Browner WS, Cummings SR 1996 Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. JAMA 276:1404-1408
37. Mosselman S, Polman J, Dijkema R 1996 ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49-53
38. Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, Winter MA, Yang NN, Dodge JA 1997 Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci 94:14105-14110
39. Furr BJA, Jordan VC 1984 The pharmacology and clinical uses of tamoxifen Pharmacol Therap 25:127-205
40. Jordan VC 1992 Overview from the international conference on long-term tamoxifen therapy for breast cancer. J Natl Cancer Inst 84:231-234
41. Gottardis MM, Robinson SP, Satyaswaroop PS, Jordan VC 1988 Contrasting actions of tamoxifen on endometrial and breast tumour growth. Cancer Res 48:812-815
42. McDonnell DP, Clemm DL, Herman T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669
43. Smith CL, Nawaz Z, O'Malley BW 1997 Coactivators and corepressors regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666
44. McDonald CC, Stewart HJ 1991 Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J 303:435-437
45. Gold E, Stapley S, Goulding A 1994 Tamoxifen and norethisterone: effects on plasma cholesterol and total body calcium content in the estrogen-deficient rat. Horm Metab Res 26:100-103
46. Gylling G, Mantyla E, Miettinen TA 1992 Tamoxifen decreases serum cholesterol by inhibiting cholesterol synthesis. Atherosclerosis 96:245-247